Business Description
T.MAN Pharmaceutical PCL
ISIN : THC209010006
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.7 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 1.74 | |||||
Interest Coverage | 43.11 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.98 | |||||
9-Day RSI | 58.54 | |||||
14-Day RSI | 54.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.98 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 673.11 | |||||
Days Sales Outstanding | 410.81 | |||||
Days Payable | 449.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 46.86 | |||||
Operating Margin % | 22.32 | |||||
Net Margin % | 19.09 | |||||
FCF Margin % | 43.17 | |||||
ROE % | 6.03 | |||||
ROA % | 3.86 | |||||
ROIC % | 5.05 | |||||
ROC (Joel Greenblatt) % | 7.08 | |||||
ROCE % | 6.86 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 65.98 | |||||
PE Ratio without NRI | 65.98 | |||||
PS Ratio | 12.6 | |||||
PB Ratio | 3.7 | |||||
Price-to-Tangible-Book | 3.77 | |||||
Price-to-Free-Cash-Flow | 29.16 | |||||
Price-to-Operating-Cash-Flow | 21.52 | |||||
EV-to-EBIT | 55.71 | |||||
EV-to-EBITDA | 55.71 | |||||
EV-to-Revenue | 12.8 | |||||
EV-to-FCF | 28.18 | |||||
Price-to-Graham-Number | 3.33 | |||||
Price-to-Net-Current-Asset-Value | 12.35 | |||||
Earnings Yield (Greenblatt) % | 1.81 | |||||
FCF Yield % | 3.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
T.MAN Pharmaceutical PCL Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ฿) | 517.951 | ||
EPS (TTM) (฿) | 0.247 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 54.34 | ||
14-Day ATR (฿) | 0.456835 | ||
20-Day SMA (฿) | 16.11 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (฿) | 15.4 - 19.3 | ||
Shares Outstanding (Mil) | 400 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
T.MAN Pharmaceutical PCL Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
T.MAN Pharmaceutical PCL Stock Events
Event | Date | Price(฿) | ||
---|---|---|---|---|
No Event Data |
T.MAN Pharmaceutical PCL Frequently Asked Questions
What is T.MAN Pharmaceutical PCL(BKK:TMAN)'s stock price today?
When is next earnings date of T.MAN Pharmaceutical PCL(BKK:TMAN)?
Does T.MAN Pharmaceutical PCL(BKK:TMAN) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |